Sericin cream reduces pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled experimental study

BMC Nephrology

Ouppatham Supasyndh¹  Nipaporn Bang²  Tippawan Siritientong²  Orathai Keongamaroon²  Pornanong Aramwit² 

[1]Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand

[2]Bioactive Resources for Innovative Clinical Applications Research Unit and Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand

关键词: Pigmentation;    Inflammation;    Hydration;    Sericin;    Hemodialysis;    Pruritus;   

Others  :  1083092
DOI  :  10.1186/1471-2369-13-119

 received in 2012-02-06, accepted in 2012-09-22,  发布年份 2012

【 摘 要 】

Background

Uremic pruritus (UP) is a significant complication in ESRD patients and substantially impairs their quality of life. UP is considered to be a skin manifestation of chronic inflammation. Because sericin can suppress the release of pro-inflammatory cytokines, the purpose of this study was to investigate the short-term safety and efficacy of sericin cream for treating UP in hemodialysis patients.

Methods

This study used a double-blind design to investigate the effects of random topical administration of sericin cream and cream base (placebo) on either the right or left extremities of hemodialysis patients for 6 weeks. Skin hydration, irritation and pigmentation were evaluated every 2 weeks using Skin Diagnostic SD27. The visual analog scale for itching was also evaluated every 2 weeks, and the Kidney Disease Quality of Life Short Form was performed on the day of each patient’s enrollment and after 6 weeks of treatment.

Results

Fifty dialysis patients were enrolled, 47 of which completed the study. The hydration of the skin of the patients’ extremities increased significantly after administration of sericin cream; significant differences were found between sericin treatment and control after 6 weeks of treatment (p = 0.041 for arms and p = 0.022 for legs, respectively). Moreover, a significant difference was also found in skin irritation between the two treatments (p = 0.013 for arms and p = 0.027 for legs, respectively). At the end of the study, the skin pigmentation level was significantly reduced on both the arms (p = 0.032) and legs (p = 0.021) of the sericin-treated side compared with the side treated with cream base. The mean itching score decreased significantly from moderate to severe at the time of enrollment to mild pruritus after 6 weeks of treatment (p = 0.002). A better quality of life was found in all domains tested although statistically significant differences before and after treatment was found only in the patients’ pain scores, the effect of kidney disease on daily life, sleep quality and symptoms or problems related to kidney disease.

Conclusions

We conclude that sericin cream has a high potential for reducing UP in hemodialysis patients.

The trial registration number of this study is ISRCTN16019033; its public title is “sericin cream reduces pruritus in hemodialysis patients”.

【 授权许可】

   
2012 Aramwit et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Feramisco JD, Berger TG, Steinhoff M: Innovative management of pruritus. Dermatol Clin 2010, 28(3):467-478.
• [2]Patel TS, Freedman BI, Yosipovitch G: An update on pruritus associated with CKD. Am J Kidney Dis 2007, 50(1):11-20.
• [3]Mettang M, Weisshaar E: Pruritus: control of itch in patients undergoing dialysis. Skin Therapy Lett 2010, 15(2):1-5.
• [4]Chen YC, Chiu WT, Wu MS: Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. Am J Kidney Dis 2006, 48(1):69-76.
• [5]Urbonas A, Schwartz RA, Szepietowski JC: Uremic pruritus–an update. Am J Nephrol 2001, 21(5):343-350.
• [6]Virga G, Visentin I, La Milia V, Bonadonna A: Inflammation and pruritus in haemodialysis patients. Nephrol Dial Transplant 2002, 17(12):2164-2169.
• [7]Akhyani M, Ganji MR, Samadi N, Khamesan B, Daneshpazhooh M: Pruritus in hemodialysis patients. BMC Dermatol 2005, 5:7. BioMed Central Full Text
• [8]Pisoni RL, Wikstrom B, Elder SJ, Akizawa T, Asano Y, Keen ML, Saran R, Mendelssohn DC, Young EW, Port FK: Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006, 21(12):3495-3505.
• [9]Wikstrom B: Itchy skin–a clinical problem for haemodialysis patients. Nephrol Dial Transplant 2007, 22(Suppl 5):v3-7.
• [10]Narita I, Alchi B, Omori K, Sato F, Ajiro J, Saga D, Kondo D, Skatsume M, Maruyama S, Kazama JJ, et al.: Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 2006, 69(9):1626-1632.
• [11]Zhang YQ: Applications of natural silk protein sericin in biomaterials. Biotechnol Adv 2002, 20(2):91-100.
• [12]Aramwit P, Sangcakul A: The effects of sericin cream on wound healing in rats. Biosci Biotechnol Biochem 2007, 71(10):2473-2477.
• [13]Zhaorigetu S, Yanaka N, Sasaki M, Watanabe H, Kato N: Inhibitory effects of silk protein, sericin on UVB-induced acute damage and tumor promotion by reducing oxidative stress in the skin of hairless mouse. J Photochem Photobiol B 2003, 71(1–3):11-17.
• [14]Zhaorigetu S, Yanaka N, Sasaki M, Watanabe H, Kato N: Silk protein, sericin, suppresses DMBA-TPA-induced mouse skin tumorigenesis by reducing oxidative stress, inflammatory responses and endogenous tumor promoter TNF-alpha. Oncol Rep 2003, 10(3):537-543.
• [15]Aramwit P, Damrongsakkul S, Kanokpanont S, Srichana T: Properties and antityrosinase activity of sericin from various extraction methods. Biotechnol Appl Biochem 2010, 55(2):91-98.
• [16]Aramwit P, Siritientong T, Kanokpanont S, Srichana T: Formulation and characterization of silk sericin-PVA scaffold crosslinked with genipin. Int J Biol Macromol 2010, 47(5):668-675.
• [17]Aramwit P, Kanokpanont S, De-Eknamkul W, Srichana T: Monitoring of inflammatory mediators induced by silk sericin. J Biosci Bioeng 2009, 107(5):556-561.
• [18]Gupta MA, Gupta AK, Kirkby S, Weiner HK, Mace TM, Schork NJ, Johnson EH, Ellis CN, Voorhees JJ: Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol 1988, 124(7):1052-1057.
• [19]Sprague KU: The Bombyx mori silk proteins: characterization of large polypeptides. Biochemistry 1975, 14(5):925-931.
• [20]Kato N, Sato S, Yamanaka A, Yamada H, Fuwa N, Nomura M: Silk protein, sericin, inhibits lipid peroxidation and tyrosinase activity. Biosci Biotechnol Biochem 1998, 62(1):145-147.
• [21]Schwartz IF, Iaina A: Uraemic pruritus. Nephrol Dial Transplant 1999, 14(4):834-839.
• [22]Mettang T, Pauli-Magnus C, Alscher DM: Uraemic pruritus–new perspectives and insights from recent trials. Nephrol Dial Transplant 2002, 17(9):1558-1563.
• [23]Aramwit P, Kanokpanont S, Punyarit P, Srichana T: Effectiveness and Inflammatory Cytokines Induced by Sericin Compared to Sericin in Combination with Silver Sulfadiazine Cream on Wound Healing. Wounds 2009, 21(8):198-206.
• [24]Berger TG, Steinhoff M: Pruritus and renal failure. Semin Cutan Med Surg 2011, 30(2):99-100.
• [25]Duque MI, Thevarajah S, Chan YH, Tuttle AB, Freedman BI, Yosipovitch G: Uremic pruritus is associated with higher kt/V and serum calcium concentration. Clin Nephrol 2006, 66(3):184-191.
• [26]Kimmel M, Alscher DM, Dunst R, Braun N, Machleidt C, Kiefer T, Stulten C, van der Kuip H, Pauli-Magnus C, Raub U, et al.: The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant 2006, 21(3):749-755.
• [27]Lugon JR: Uremic pruritus: a review. Hemodial Int 2005, 9(2):180-188.
• [28]Dugas-Breit S, Schopf P, Dugas M, Schiffl H, Rueff F, Przybilla B: Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus. J Dtsch Dermatol Ges 2005, 3(5):343-347.
• [29]Szepietowski J, Thepen T, van Vloten WA, Szepietowski T, Bihari IC: Pruritus and mast cell proliferation in the skin of haemodialysis patients. Inflamm Res 1995, 44(Suppl 1):S84-85.
• [30]Matsumoto M, Ichimaru K, Horie A: Pruritus and mast cell proliferation of the skin in end stage renal failure. Clin Nephrol 1985, 23(6):285-288.
• [31]Young AW Jr, Sweeney EW, David DS, Cheigh J, Hochgelerenl EL, Sakai S, Stenzel KH, Rubin AL: Dermatologic evaluation of pruritus in patients on hemodialysis. N Y State J Med 1973, 73(22):2670-2674.
• [32]Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA: Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994, 45(3):890-896.
• [33]Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimburger O, Cederholm T, Girndt M: IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia–the good, the bad, and the ugly. Kidney Int 2005, 67(4):1216-1233.
• [34]Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, Pinkney JH: Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 2001, 16(6):1189-1197.
• [35]Portugal-Cohen M, Oron M, Ma'or Z, Boaz M, Shtendik L, Biro A, Cernes R, Barnea Z, Kazir Z, Kohen R: Noninvasive skin measurements to monitor chronic renal failure pathogenesis. Biomed Pharmacother 2011, 65(4):280-285.
• [36]Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD: Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 2005, 67(5):1812-1820.
• [37]Ponticelli C, Bencini PL: Uremic pruritus: a review. Nephron 1992, 60(1):1-5.
• [38]Wang H, Yosipovitch G: New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. Int J Dermatol 2010, 49(1):1-11.
• [39]Bencini PL, Montagnino G, Citterio A, Graziani G, Crosti C, Ponticelli C: Cutaneous abnormalities in uremic patients. Nephron 1985, 40(3):316-321.
• [40]Avermaete A, Altmeyer P, Bacharach-Buhles M: Skin changes in dialysis patients: a review. Nephrol Dial Transplant 2001, 16(12):2293-2296.
• [41]Dyachenko P, Shustak A, Rozenman D: Hemodialysis-related pruritus and associated cutaneous manifestations. Int J Dermatol 2006, 45(6):664-667.
• [42]Chiu YL, Chen HY, Chuang YF, Hsu SP, Lai CF, Pai MF, Yang SY, Peng YS: Association of uraemic pruritus with inflammation and hepatitis infection in haemodialysis patients. Nephrol Dial Transplant 2008, 23(11):3685-3689.
• [43]Yang JY, Huang JW, Chiang CK, Pan CC, Wu KD, Tsai TJ, Chen WY: Higher plasma interleukin-18 levels associated with poor quality of sleep in peritoneal dialysis patients. Nephrol Dial Transplant 2007, 22(12):3606-3609.
• [44]Chiu YL, Chuang YF, Fang KC, Liu SK, Chen HY, Yang JY, Pai MF, Peng YS, Wu KD, Tsai TJ: Higher systemic inflammation is associated with poorer sleep quality in stable haemodialysis patients. Nephrol Dial Transplant 2009, 24(1):247-251.
• [45]Chen HY, Chiang CK, Wang HH, Hung KY, Lee YJ, Peng YS, Wu KD, Tsai TJ: Cognitive-behavioral therapy for sleep disturbance in patients undergoing peritoneal dialysis: a pilot randomized controlled trial. Am J Kidney Dis 2008, 52(2):314-323.
• [46]Aramwit P, Kanokpanont S, Nakpheng T, Srichana T: The effect of sericin from various extraction methods on cell viability and collagen production. Int J Mol Sci 2010, 11(5):2200-2211.
• [47]Takasu Y, Yamada H, Tsubouchi K: Isolation of three main sericin components from the cocoon of the silkworm, Bombyx mori. Biosci Biotechnol Biochem 2002, 66(12):2715-2718.
• [48]Mathur VS, Lindberg J, Germain M, Block G, Tumlin J, Smith M, Grewal M, McGuire D: A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol 2010, 5(8):1410-1419.
• [49]Okada K, Matsumoto K: Effect of skin care with an emollient containing a high water content on mild uremic pruritus. Ther Apher Dial 2004, 8(5):419-422.
• [50]Wahlgren CF, Ekblom A, Hagermark O: Some aspects of the experimental induction and measurement of itch. Acta Derm Venereol 1989, 69(3):185-189.
• [51]Homjean K, Sakthong P: Translation and cognitive testing of the Thai version of the kidney disease quality of life short-form questionnaires version 1.3. Thai J Pharm Pract 2010, 2(1):3-14.
• [52]Park HJ, Kim S, Yong JS, Han SS, Yang DH, Meguro M, Han CW, Kohzuki M: Reliability and validity of the Korean version of Kidney Disease Quality of Life instrument (KDQOL-SF). Tohoku J Exp Med 2007, 211(4):321-329.
• [53]Al Jumaih A, Al-Onazi K, Binsalih S, Hejaili F, Al-Sayyari A: A Study of Quality of Life and its Determinants among Hemodialysis Patients Using the KDQOL-SF Instrument in One Center in Saudi Arabia. Arab J Nephrol Transplant 2011, 4(3):125-130.